- With the FDA approval, the company would be able to help medical professionals integrate 3D mapping with ablation to advance atrial fibrillation treatment.
- The approval also further expands the company’s existing cardiac ablation tools portfolio.
Abbott Laboratories (Abbott), an American pharmaceutical company, has reportedly announced that its new ablation catheter, TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath Sensor Enabled), has been approved by the United States Food & Drug Administration (FDA).
Reports cite, the approval would be further expanding the healthcare company’s existing cardiac ablation tools portfolio, which contains tools capable of integrating with Abbott’s cardiac mapping system EnSite Precision™, to help medical professionals develop clearer heart images when conducting cardiac ablation procedures.
According to a report by Diagnostic & Interventional Cardiology, the new Abbott ablation catheter has been specifically designed to help medical professionals in effectively and accurately treating atrial fibrillation (AFib). Similar to the company’s other range of ablation treatment & sensor-enabled mapping catheters, the new TactiCath Sensor Enabled facilitates clearer & precise heart images which are overlaid with additional real-time electrical activity data.
Moreover, the catheter also uses an advanced ergonomic design, that is incorporated in the company’s existing range of FlexAbility™ ablation catheter, to facilitate a superior maneuverability and reach when conducting cardiac ablation procedures.
An electrophysiologist at Sequoia Hospital and one of the first medical professionals to use the new FDA-approved catheter, Dr. Roger Winkle, M.D. stated that Cardiac ablation has now become a go-to therapy when treating conditions such as atrial fibrillation due to the enhancements available in the technology today. Dr. Winkle further added that Abbott’s new catheter represents one such significant enhancement, and provides an easy-to-use, yet incredible powerful advanced technology combination to enhance ablation procedures.
The Medical Director of Electrophysiology business at Abbott, Srijoy Mahapatra, M.D., FHRS, stated that the TactiCath SE directly supports the company’s goal of endorsing effective, safe and fast cardiac ablation procedures. The company aims to equip more medical professionals with advanced ablation catheters coupled with market-leading cardiac mapping to treat AFib.
